Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ANI Pharmaceuticals, Inc. - Common Stock (NQ:ANIP)

91.79 -1.07 (-1.15%)
Streaming Delayed Price Updated: 9:45 AM EDT, Oct 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ANI Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
3 Profitable Stocks We’re Skeptical Of
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
ANI Pharmaceuticals Inc (NASDAQ:ANIP) Screens as High Growth Momentum Stock Meeting Minervini Trend Template
ANI Pharmaceuticals (ANIP) combines strong technical uptrend with explosive earnings and sales growth, fitting a proven strategy for spotting potential market leaders. 
Via Chartmill
ANI Pharmaceuticals Inc (NASDAQ:ANIP) Combines Strong Growth Momentum with Bullish Technical Setup
ANI Pharmaceuticals (ANIP) shows strong growth momentum with 76% EPS growth and a positive technical setup, signaling a potential breakout opportunity. 
Via Chartmill
ANI Pharmaceuticals (ANIP): Buy, Sell, or Hold Post Q2 Earnings?
ANI Pharmaceuticals has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 37.4% to $92.06 per share while the index has... 
Via StockStory
Topics Stocks Supply Chain
6 Analysts Have This To Say About ANI Pharmaceuticals
 
Via Benzinga
4 Analysts Have This To Say About ANI Pharmaceuticals
 
Via Benzinga
ANI Pharma Stock Shoots Through The Roof On Friday: CEO’s Confidence On Trump Tariff Impact, Guidance Lift, Upbeat Q2 Among Key Factors
Via Stocktwits
Topics Government
3 Low-Volatility Stocks We’re Skeptical Of
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. 
Via StockStory
3 Small-Cap Stocks We Approach with Caution
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a... 
Via StockStory
ANI Pharmaceuticals Inc (NASDAQ:ANIP) Presents a High Growth Momentum and Technical Breakout Opportunity
ANI Pharmaceuticals (ANIP) shows strong earnings acceleration, robust sales growth, and bullish analyst revisions. With a top technical rating, it's forming a base near highs, signaling a potential... 
Via Chartmill
3 Unpopular Stocks with Questionable Fundamentals
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other... 
Via StockStory
Earnings Preview For ANI Pharmaceuticals
 
Via Benzinga
3 Russell 2000 Stocks with Questionable Fundamentals
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher... 
Via StockStory
A Look Back at Generic Pharmaceuticals Stocks’ Q2 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Pack
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the generic pharmaceuticals industry, including Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Generic Pharmaceuticals Stocks Q2 Earnings: ANI Pharmaceuticals (NASDAQ:ANIP) Best of the Bunch
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including ANI Pharmaceuticals (NASDAQ:ANIP) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
ANI Pharmaceuticals Inc (NASDAQ:ANIP) Shows Strong Momentum and Growth, Fitting Minervini's Trend-Following Criteria
ANI Pharmaceuticals (ANIP) shows strong technical momentum and accelerating earnings growth, making it a compelling candidate for high-growth momentum investors. 
Via Chartmill
1 Mooning Stock for Long-Term Investors and 2 That Underwhelm
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro... 
Via StockStory
Topics Emissions
Q2 Earnings Roundup: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Segment
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q2, starting with... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
3 Healthcare Stocks We’re Skeptical Of
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, and over the past six... 
Via StockStory
Topics Stocks
Azenta, LifeStance Health Group, BioMarin Pharmaceutical, AMN Healthcare Services, and ANI Pharmaceuticals Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer... 
Via StockStory
Topics Earnings Economy
ANIP Q2 Deep Dive: Rare Disease Expansion Fuels Outperformance, Generics Maintain Solid Trajectory
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 53.1% year on year to $211.4 million. The... 
Via StockStory
Why ANI Pharmaceuticals (ANIP) Stock Is Up Today
Shares of specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) jumped 18.4% in the morning session after the company reported second-quarter earnings and revenue that surpassed analyst... 
Via StockStory
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
ANI Pharmaceuticals Inc (NASDAQ:ANIP) Reports Record Q2 2025 Earnings, Beats Estimates and Raises Full-Year Guidance
ANI Pharmaceuticals reports record Q2 2025 earnings, beating estimates with $211.4M revenue and $1.80 EPS. Shares surge 6.5% as company raises full-year guidance. 
Via Chartmill
Topics Earnings
ANI Pharmaceuticals’s (NASDAQ:ANIP) Q2: Strong Sales, Stock Soars
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) announced better-than-expected revenue in Q2 CY2025, with sales up 53.1% year on year to $211.4 million. The company’s full-year... 
Via StockStory
Earnings Scheduled For August 8, 2025
 
Via Benzinga
ANI Pharmaceuticals (ANIP) Q2 Earnings: What To Expect
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) will be reporting earnings this Friday before the bell. Here’s what to look for. 
Via StockStory
Topics Government World Trade
Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals
From CG Oncology Inc.
Via GlobeNewswire
Q1 Earnings Highs And Lows: Amneal (NASDAQ:AMRX) Vs The Rest Of The Generic Pharmaceuticals Stocks
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the generic pharmaceuticals industry, including Amneal (NASDAQ:AMRX) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Q1 Earnings Highs And Lows: Viatris (NASDAQ:VTRS) Vs The Rest Of The Generic Pharmaceuticals Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q1, starting with... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.